DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from $63. The firm noted that the company is overcoming recent operational hurdles while its stock remains at historical lows. Morgan Stanley expects the full scope of this recovery to be visible by early next year and believes that investors are currently undervaluing the G7 rollout’s margin potential. Earlier on ...

Core Insights - DexCom, Inc. has received FDA clearance for Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy [1] - The Dexcom Smart Basal will utilize data from the Dexcom G7 15 Day sensor and logged doses to provide personalized daily recommendations for optimizing long-acting insulin doses [1] Company Summary - DexCom, Inc. is recognized as the global leader in glucose biosensing technology [1] - The introduction of Dexcom Smart Basal represents a significant advancement in diabetes management, specifically targeting adults with Type 2 diabetes [1] Industry Impact - The FDA clearance of Dexcom Smart Basal is expected to enhance the management of Type 2 diabetes, potentially improving patient outcomes through personalized insulin dosing [1]